SCHEMBL3244636

SCHEMBL3244636

CCCOc1cc(Cl)ccc1C(=O)NC(c1ccccc1)C1(N(C)C)CCCC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.43
PNLIP P16233 1/20 0.42
ADRB1 P08588 5/20 0.40
ADRB3 P13945 5/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
TP53 P04637 1/20 0.38
MAPT P10636 2/20 0.37
PKM P14618 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SLC6A9 P48067 1/20 0.37
AKR1C3 P42330 2/20 0.36
GALR1 P47211 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
HIF1A Q16665 1/20 0.36
FOLH1 Q04609 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3237145 0.87 AVPR2 (0.43) MAPTL3MBTL1SLC6A9MEN1KMT2A
SCHEMBL3244199 0.83 MEN1 (0.49) CYP2C19MAPTSLC6A9MEN1KMT2A
SCHEMBL3239983 0.82 UTS2R (0.42) CYP3A4CYP2D6CYP2C9CYP2C19SLC6A9
SCHEMBL3237602 0.81 GPR139 (0.50) CYP3A4CYP2D6CYP2C9CYP2C19SLC6A9
SCHEMBL3238239 0.78 CHRM1 (0.42) CYP3A4CYP2D6CYP2C9CYP2C19TP53
SCHEMBL3239515 0.77 KCNA3 (0.44) CYP3A4CYP2D6CYP2C9CYP2C19TP53
SCHEMBL4355245 0.77 MEN1 (0.41) CYP3A4CYP2D6CYP2C9CYP2C19TP53
SCHEMBL3238270 0.76 ALDH1A1 (0.57) TP53L3MBTL1SLC6A9MEN1KMT2A
SCHEMBL3245066 0.75 P2RX7 (0.43) SLC6A9MEN1KMT2A
SCHEMBL3238721 0.75 ALDH1A1 (0.46) PKMSLC6A9MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
WO-2006067423-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 THRB 2845/4885PNLIP 3107/4885ADRB1 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.